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none has detectable bcr/abl transcripts in blood or marrow. One
patient (CML-CP3) with cytogenetic relapse at D  118 had a
fourth remission after withdrawal of immunosuppression and con-
tinued imatinib but developed hematological relapse at D  429.
Conclusions: We conclude that imatinib therapy can be safely
prescribed early after myeloablative allogeneic HCT at a dose-
intensity comparable to that used in general oncology. Preliminary
efﬁcacy data are encouraging and worthy of further study (Table1).
Table 1. Patient Characteristics and Outcomes
ALL
(n  12)
CML
(n  6)
Pretransplant characteristics
Disease phase, N CR1 10, CR2 2
AP 2, CP2 2, CP3
2
Patients with MRD1 present, N 9 6
Median age, years (range) 36 (5–49) 45 (36–62)
Related donor, unrelated
donor, N 5, 7 2, 4
Peripheral blood, marrow,
cord blood, N 8, 3, 1 4, 1, 0
Posttransplant outcomes
Imatinib therapy start day,
median (range) 28 (24–39) 29 (25–36)
Imatinib therapy, days of,
median (range) 183 (3–381) 243 (89–353)
Average daily imatinib doses,
milligrams
<Day 90, median (range) 400 (2122–400) 400 (novariance)
>Day 90, median (range) 400 (2502–550) 400 (novariance)
Survival, days, median (range) 214 (27–600) 511 (130–627)
Molecular
remission/completed
therapy, N/N 4/4 3/4
Molecular remission/continue
Imatinib, N/N 8/8 2/2
1MRD  minimal residual leukemia by cytogenetic and/or molec-
ular methods.
2Two children did not receive 400 mg per day but received close to
340 mg/m2/day.
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DIFFERENCES IN THE PHENOTYPE AND IN VIVO ANTI-TUMOR ACTIV-
ITY OF WT1 SPECIFIC AND EBV-SPECIFIC T-CELLS GENERATED IN
VITRO FOR ADOPTIVE IMMUNOTHERAPY
Doubrovina, E.1, Dupont, J.1, Kanaeva, E.1, Doubrovin, M.1,
O’Reilly, R.1 Memorial Sloan-Kettering Cancer Center, New York, NY.
Our studies in SCIDmouse/human tumor xenograft models have
demonstrated that T cells sensitized with autologous EBV BLCL
in vitro will, following intravenous transfer into mice bearing
tumors varying in HLA type and expression of EBV antigens,
selectively accumulate in EBV tumors co-expressing the T cell’s
HLA restricting allele, and will proliferate and persist in these
tumors through there complete regression. In contrast while T
cells sensitized against WT1 peptides presented by peptide-loaded
autologous DCs or EBV BLCL in vitro also exhibit HLA-re-
stricted accumulation in WT1 tumor xenografts and induce
signiﬁcant inhibition of tumor growth, they persist only for periods
of 8 days following adoptive transfer. By day 15, the T cells were
no longer detectable in the tumors, following which the regrowth
of WT1 expressing tumors was again observed. Accordingly, we
compared T cells sensitized in vitro with autologous EBV BLCL
alone or with EBV BLCL loaded either with the pool of overlap-
ping 15-mers spanning over WT1 sequence or transduced to
express WT1. Antigen-speciﬁc T cells were then characterized as
to their speciﬁcity and HLA restriction. Antigen-reactive T cells
were then isolated on the basis of IFN production in response to
secondary restimulation with APCs bearing targeted peptides and
the appropriate restricting HLA alleles and evaluated for their
phenotype and tumor-speciﬁc activity. Both CD4 and CD8
EBV-speciﬁc T cells exhibited HLA-restricted lysis of EBV
tumor cells while the CD8 WT1 speciﬁc T cells consistently
lizedWT1 tumors bearing HLA restricting HLA class I allele. The
CD4 T cells were not cytotoxic. The WT1-speciﬁc and EBV-
speciﬁc CD4 T cells did not differ in phenotype. However, while
CD8 T cells speciﬁc for EBV expressed an effector memory
phenotype (CD3 CD8 CCR7 CD45RA CD45RO
CD62L CD25), the WT1 speciﬁc CD8 T cells were predom-
inantly of a central memory type (CD3 CD8 CCR7
CD45RA CD45RO CD62L CD25). These studies suggest
that T cells generated against WT1 in vitro may be relatively
deﬁcient in effector memory T cells required to induce complete
tumor regression in vivo.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR MALIG-
NANCIES USING UMBILICAL CORD BLOOD UNITS (UCB) THAT WERE
NOT RED BLOOD CELL DEPLETED
Chow, R.1, Nademanee, A.2, Rosenthal, J.2, Karanes, C.2,
Graham, M.3, Tan, P.4, Jaing, T.-H.5, Gjertson, D.6, Petz, L.1 1.
StemCyte International Cord Blood Center, Arcadia, CA; 2. City of
Hope National Medical Center, Duarte, CA; 3. University of Arizona
Medical Center, Tuscon, AZ; 4. Mount Elizabeth Hospital, Singapore,
Singapore; 5. Chung Gung Memorial Hospital, Linko, Taiwan; 6.
UCLA Medical Center, Los Angeles, CA.
Cell dosage is a limiting factor for UCB HSCT, especially for adult
patients. Most UCB banks practice red cell depletion (RCD) tech-
niques to save storage space, which incur signiﬁcant nucleated cell loss
after processing. One method of minimizing cell loss and still reduce
volume after processing is to deplete plasma (PD), but not the red
blood cells. Not washing UCB after thawing also minimizes cell loss.
A large, racially diverse PD UCB inventory of 18,000 units is now
available on stem cell registries. A retrospective analysis was per-
formed on 70 patients with malignancies without prior HSCT who
were transplanted during remission with PD UCB. There were 28
ALL, 16 AML, 8 CML, 7MDS/RA/RAEB, 3 JMML, and 8 others.
Of the ALL/AML/CML cases with available information, there were
19 1CR/CP, 10 2CR, and 9 3CR/CP. The median age of patients was
5.8 years old (range 0.5–54); median weight 23 kg (range 5–84); male
63%. Transplant characteristics indicated a median # HLA ABDR
matches of 5.0 (11-6/6; 23-5/6; 27-4/6; 8-/6; 1-/6;) median pre-freeze
TNC dose 6.4 107/kg; median post-thaw TNC dose as reported by
TC 5.3  107/kg; median pre-freeze CD34 dose 2.5  105/kg;
transplants outside of U.S. 24%; double unit transplant 14%; non-
myeloablative 7%. Forty-seven percent of the transplanted UCBwere
washed post-thaw (W), 33% were infused without post-thaw wash
(NW), with 20% of the units without available post-thaw data. Me-
dian time to engraftment for ANC 500 (n  66), platelet 20K (n 
52), and 50K (n 50) were 24 days (range 7–49 days), 53 days (range
15–94 days), and 63 days (range 37–132 days), respectively. Median
time to engraftment for W versus NW were 28 versus 23 days for
ANC500, and 55 versus 49 days for platelet 20K, respectively. The
unadjusted cumulative incidence (C.I.) of ANC500 and platelet 20K
and 50K engraftments are 93  3%, 76  6%, and 75  6%,
respectively. The incidence of reported grade II-IV and III-IV acute
GVHD were 37% and 20%, respectively. Twelve percent developed
limited chronic GVHD and 15% developed extensive chronic
GVHD. With a median follow-up of 282 days (range 50–1263 days),
the Kaplan-Meier estimates of 1-year TRM, OS and relapse-free
survival were 20  6%, 67  6%, and 59  7%, respectively. These
results demonstrate that HSCT using unrelated PD UCB can be
performed safely and effectively in patients with malignancies, and
post-thaw wash may not be necessary.
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OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION AFTER ADDING HIGH-DOSE CYTARABINE TO THE CONVEN-
TIONAL Cy/TBI CONDITIONING REGIMEN FOR THE TREATMENT OF
PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIA
Yoo, K.H.1, Kook, H.2, Sung, K.W.1, Jung, H.-L.1, Koo, H.H.1,
Baek, H.J.2, Hwang, T.J.2 1. Department of Pediatrics, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul,
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Korea; 2. Department of Pediatrics, Chonnam National University
Hospital, Chonnam National University School of Medicine, Gwangju,
Korea.
Philadelphia-chromosome-positive (Ph) acute lymphoblastic
leukemia (ALL) accounts for 3–5% of childhood ALL, and allo-
geneic hematopoietic stem cell transplantation (HSCT) is consid-
ered to be the best way to cure the relatively rare and aggressive
subtype of ALL. Cytarabine is an effective agent in both lymphoid
and myeloid leukemia, and high-dose cytarabine (HDC) has been
used to treat patients with ALL who had relapsed or had been
refractory to the standard induction chemotherapy. From this
point of view, we postulated that the addition of HDC to the
standard conditioning regimen might decrease the relapse rate
through more effective eradication of residual leukemia before
transplant. So, we investigated the feasibility of HDC-containing
conditioning for the treatment of children with Ph ALL. Be-
tween February 2002 and May 2005, 10 consecutive patients with
Ph ALL, including one who had presented with CML in lym-
phoid blastic phase, aged 3.5–12.8 years (median age 9.4 years)
received allogeneic HSCT at our two cooperative institutions. The
median time from diagnosis to transplant was 6 months (range,
3–10 mo). Two patients (20%) were not in CR1 at transplant. The
sources of stem cells were as follows: unrelated bone marrow (n 
5), unrelated cord blood (n  4), matched sibling bone marrow
(n  1). The conditioning regimen included HDC (3 g/m2/dose
every 12 h  4 doses, total 12 g/m2), cyclophosphamide (60
mg/kg/day  2 days, total 120 mg/kg), and total body irradiation
(TBI). TBI was delivered in 2 different manners according to the
each institutional guideline (1000 cGy/3 Fr/3 day, n  5; 1320
cGy/11 Fr/4 day, n  5). Cyclosporine with or without other
agents was used for GVHD prophylaxis. The neutrophil recovery
was attained in all recipients at a median of 20.5 days (range, 11–44
days) and the platelet engraftment also occurred in all patients at a
median of 26.5 days (range, 13–148 days). Grade 2-4 and grade 3-4
acute GVHD were developed in 4 (40%) and 2 (20%) patients,
respectively. Three patients (30%) developed chronic GVHD (2
limited, 1 extensive). All but one patient are alive disease-free with
a median follow-up of 21 months (range, 4–39 months). There was
no relapse and the only event was a chronic pulmonary GVHD
with bronchiolitis obliterans leading to death in 1 patient. The
3-year estimated event-free survival was 83.3%. In conclusion, our
results suggest that adding HDC to the standard Cy/TBI condi-
tioning is feasible in allogeneic HSCT for pediatric patients with
Ph ALL.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IN
ADULTS WITH ACUTE MYELOID LEUKEMIA (AML) – A SINGLE PRO-
GRAM EXPERIENCE
Obenchain, R.1, Ruffner, K.1,2, Stokes, D.2, Wu, W.1, Brandt, S.1,2,
Chinratanalab, W.2, Jagasia, M.1, Kassim, A.1, Greer, J.1,
Morgan, D.1,2, Stein, R.1, Vusirikala, M.1,2, Schuening, F.1,
Goodman, S.1,2 1. Vanderbilt University, Nashville, TN; 2. Veterans
Administration, Nashville, TN.
From 1/00 to 4/05, 93 patients (pts) with AML underwent allo
HSCT at the VU/VA SCT program. Variables including donor
type, stem cell source, regimen intensity, and degree of HLA
matching were analyzed for their effect on OS and TTP. Median
age at transplant was 47 (19–66). 85 pts (91%) had poor risk
disease, deﬁned as prior MDS or MPD (n  17), poor-risk cyto-
genetics (n  6), refractory disease (n  4), relapsed disease (n 
15), history of chemotherapy and/or radiotherapy for a prior ma-
lignancy (n 4), CR2 (n 35), or requiring	1 cycle of induction
to achieve CR1 (n 4). Regimens were either full-dose (BuCy and
CyTBI) or reduced-dose (FluBu, FluBuTBI, or FluTBI). Of the 93
pts, 62 (67%) had matched related donors (MRD) and 31 (33%)
had unrelated donors (URD). Both groups (MRD vs URD) were
similar in disease risk (87% vs 100% high risk), degree of HLA
matching (98% vs 77% fully matched), and regimen intensity (79%
vs 77% full-dose) but differed signiﬁcantly in stem cell source with
MRD 95% PBSC and URD 71% BM, P  .001. Day 100 mor-
tality was 11% for MRD versus 29% for URD, and all pts surviving
to day 30 engrafted (ANC	500). Median OS was 10.8 months and
was not signiﬁcantly affected by donor type, regimen intensity, or
pt age. OS was signiﬁcantly higher in pts with fully-matched
donors (median 12.9 months vs 2.4 mos, P  .027) and in pts
without high-risk disease (median not reached vs 8.0 months, P 
.040). There was also a trend towards improved survival of pts
receiving PBSC versus BM (median 13.4 mos vs 6.7, P  .062).
Interestingly, pts receiving full-dose regimens were more likely to
die of relapse than transplant-related mortality (TRM) (30 relapse
vs 16 TRM), while pts receiving reduced-dose regimens had more
TRM than relapse deaths (3 relapse vs 9 TRM, P  .02), which
may be accounted for by the higher median age of the reduced-
dose group (56 vs 43). Of the 93 pts, 35 (38%) are alive with a
median follow-up of 18.0 mos (5.5–61.8), 35 (38%) have died of
relapse, and 23 (25%) TRM. TTP was 31.4 months with censor-
ship of pts with TRM. OS at 36 months was 33%. Using a
Cox-proportional multivariate model, only disease risk approached
signiﬁcance with a hazard ratio of 3.6 (P  .079). These results
highlight the need for better anti-leukemic regimens and indicate
that allo HSCT is most beneﬁcial to pts who have chemotherapy-
responsive disease and few risk factors for TRM, but can still
salvage approximately 1/3 of patients with poor risk disease.
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THE EARLY REFERRAL FOR REDUCED-INTENSITY STEM CELL TRANS-
PLANTATION IN PATIENTS WITH Ph1 () CHRONIC MYELOGENOUS
LEUKEMIA IN CHRONIC PHASE IN THE IMATINIB ERA: RESULTS OF
THE LATIN AMERICAN COOPERATIVE ONCOHEMATOLOGY GROUP (LA-
COHG) PROSPECTIVE, MULTICENTER STUDY
Ruiz-Arguelles, G.J.1,2, Gomez-Almaguer, D.3, Morales-Toquero, A.1,
Gutierrez-Aguirre, C.H.3, Vela-Ojeda, J.4, Garcia-Ruiz-Esparza,
M.A.4, Manzano, C.1, Karduss, A.5, Sumoza, A.6, de-Souza, C.7,
Miranda, E.7, Giralt, S.8 1. Centro de Hematologia y Medicina Interna
de Puebla, Puebla, Mexico; 2. Laboratorios Clinicos de Puebla, Puebla,
Mexico; 3. Hospital Universitario de Monterrey, Monterrey, Nuevo
Leon, Mexico; 4. Centro Medico La Raza, IMSS, Mexico City, Mexico;
5. Instituto de Cancerologia. Clinica las Americas, Medellin, Colombia;
6. Universidad de Carabobo, Valencia, Venezuela; 7. Universidad de
Campinas, Sao Paulo, Brazil; 8. M. D. Anderson Cancer Center,
Houston, TX.
Using a reduced intensity stem cell transplantation (RIST)
schedule, 24 patients with Ph1 () chronic myelogenous leukemia
(CML) in ﬁrst chronic phase were prospectively allografted in 4
Latin American countries: Mexico, Brasil, Colombia, and Venezu-
ela, using HLA-identical siblings as donors. Median age of the
patients was 41 years (range 10–71); there were 8 females. Patients
received a median of 4.4  106/Kg CD34 cells. Median time to
achieve above 0.5  109/L granulocytes was 12 days, range 0–41,
whereas median time to achieve above 20  109/L platelets was
also 12 days, range 0–45. Twenty two patients are alive 81 to 830
(median 497) days after the RIST. The 830-day probability of
survival is 92%, whereas median survival has not been reached,
being above 830 days. Eleven patients (46%) developed acute
graft-versus-host disease (GVHD), whereas 7 of 23 (30%) devel-
oped chronic GVHD. Two patients died 43 and 210 days after the
RIST, one as a result of sepsis and the other one of chronic
GVHD. The 100-day mortality was 4.4 %, whereas the transplant-
related mortality was 8%. RIST for patients with CML in chronic
phase seems as an adequate therapeutic option.
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ADDITION OF RITUXIMAB TO HYPER-CVAD IN THE TREATMENT OF
CD20-POSITIVE ADULT ACUTE LYMPHOCYTIC LEUKEMIA (ALL)
Cumpston, A.1, Weisenborn, R.1, Ericson, S.1 West Virginia University
Hospitals, Morgantown, WV.
Hyper-CVAD (fractionated cyclophosphamide, vincristine,
doxorubicin, and dexamethasone) alternating with high-dose
methotrexate-cytarabine has proven to be an effective regimen in
the treatment of adult ALL. Addition of the anti-CD20 monoclo-
nal antibody rituximab to standard chemotherapy regimens has
shown signiﬁcant beneﬁt in the treatment of lymphoma and leu-
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